J J Stepan
Overview
Explore the profile of J J Stepan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vaculik J, Wenchich L, Bobelyak M, Pavelka K, Stepan J
J Endocrinol Invest
. 2022 Jan;
45(5):1039-1044.
PMID: 35079976
Objective: Although calcitriol is essential for bone healing, its serum concentrations are low after hip surgery, and they continue to decline during bone healing. This study aimed to test the...
2.
Vaculik J, Wenchich L, Bobelyak M, Pavelka K, Stepan J
J Endocrinol Invest
. 2021 Jan;
44(9):1847-1855.
PMID: 33492601
Objective: To assess the decrease in serum calcitriol concentrations after hip fracture. Methods: Serum concentrations of calcitriol, 25(OH)D, parathyroid hormone (PTH), directly measured free 25(OH)D, and indices of bone formation...
3.
Body J, Marin F, Kendler D, Zerbini C, Lopez-Romero P, Moricke R, et al.
Osteoporos Int
. 2020 Jun;
31(10):1935-1942.
PMID: 32474650
Introduction: The VERO trial was an active-controlled fracture endpoint clinical trial that enrolled postmenopausal women with severe osteoporosis. After 24 months, a 52% reduction in the hazard ratio (HR) of...
4.
Paschalis E, Gamsjaeger S, Hassler N, Fahrleitner-Pammer A, Dobnig H, Stepan J, et al.
Bone
. 2016 Nov;
95:41-46.
PMID: 27826025
Prospective, controlled clinical trials in postmenopausal osteoporosis typically compare effects of an active drug with placebo in addition to vitamin D and calcium supplementation in both treatment arms. While clinical...
5.
Lindsay R, Krege J, Marin F, Jin L, Stepan J
Osteoporos Int
. 2016 Feb;
27(8):2395-410.
PMID: 26902094
Teriparatide (TPTD) is the only currently available therapeutic agent that increases the formation of new bone tissue and can provide some remediation of the architectural defects in the osteoporotic skeleton....
6.
Hofstetter B, Gamsjaeger S, Varga F, Dobnig H, Stepan J, Petto H, et al.
Osteoporos Int
. 2014 Jul;
25(12):2709-19.
PMID: 25037600
Unlabelled: The results of the present study, involving analysis of biopsies from patients who received teriparatide for 2 years and were previously either treatment-naïve or on long-term alendronate therapy, suggest...
7.
Ferrari S, Bianchi M, Eisman J, Foldes A, Adami S, Wahl D, et al.
Osteoporos Int
. 2012 Jun;
23(12):2735-48.
PMID: 22684497
Postmenopausal osteoporosis is mainly caused by increased bone remodeling resulting from estrogen deficiency. Indications for treatment are based on low areal bone mineral density (aBMD, T-score ≤ -2.5), typical fragility...
8.
Michalska D, Luchavova M, Zikan V, Raska Jr I, Kubena A, Stepan J
Osteoporos Int
. 2012 Mar;
23(12):2885-91.
PMID: 22426952
Unlabelled: A 12-month morning teriparatide (TPTD) administration resulted in a larger increase in the lumbar spine bone mineral density (BMD) than the evening application. The results indicate that the response...
9.
Stepan J, Burr D, Li J, Ma Y, Petto H, Sipos A, et al.
Osteoporos Int
. 2010 Feb;
21(12):2027-36.
PMID: 20135094
Summary: The level of increased bone formation after 24 months of treatment with teriparatide (rhPTH (1-34), TPTD) is similar in patients who were either treatment-naïve (TN) or had lower bone...
10.
Kaptoge S, Reid D, Scheidt-Nave C, Poor G, Pols H, Khaw K, et al.
Bone
. 2006 Dec;
40(3):662-73.
PMID: 17175209
Introduction: While the determinants of BMD change have been studied in women, there have been few longitudinal studies in men. As part of the Network in Europe for Male Osteoporosis...